Market Overview

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September

Share:

NEWARK, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the Wedbush PacGrow Healthcare Conference, the H.C. Wainwright 20th Annual Global Investment Conference, and the Citi's 13th Annual Biotech Conference.

 
Wedbush PacGrow Healthcare Conference
Date: Wednesday, August 15
Time: 2:30pm Eastern Time
Location: Parker New York, New York, NY
Webcast:            http://ir.cymabay.com/events       


H.C. Wainwright 20th Annual Global Investment Conference       
Date: Wednesday, September 5
Time: 9:10am Eastern Time
Location: St. Regis Hotel, New York, NY
Webcast: http://ir.cymabay.com/events


Citi's 13th Annual Biotech Conference   
Date:  Thursday, September 6 
Time:  1-on-1 meetings only
Location:            Four Seasons Hotel, Boston, MA
   

About CymaBay 

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).

For additional information about CymaBay visit www.cymabay.com.

Contact:              
Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com

 

Primary Logo

View Comments and Join the Discussion!